IL6 and metabolic dysfunction-associated steatotic liver disease: According to previous reports, AMPK activation is involved in the inhibition of the IL-6-stimulated inflammatory response in human liver cells and mediates the antioxidant stress ability of fibroblast growth factor (FGF) one in a mouse model of nonalcoholic fatty liver disease (Nerstedt et al., 2013; Liu et al., 2020).